A systematic review of the antipsychotic properties of cannabidiol in humans

  title={A systematic review of the antipsychotic properties of cannabidiol in humans},
  author={T. Iseger and M. Bossong},
  journal={Schizophrenia Research},
  • T. Iseger, M. Bossong
  • Published 2015
  • Medicine, Psychology
  • Schizophrenia Research
  • Despite extensive study over the past decades, available treatments for schizophrenia are only modestly effective and cause serious metabolic and neurological side effects. Therefore, there is an urgent need for novel therapeutic targets for the treatment of schizophrenia. A highly promising new pharmacological target in the context of schizophrenia is the endocannabinoid system. Modulation of this system by the main psychoactive component in cannabis, Δ9-tetrahydrocannabinol (THC), induces… CONTINUE READING
    Could cannabidiol be used as an alternative to antipsychotics?
    • 19
    • Open Access
    Cannabinoids and Schizophrenia: Risks and Therapeutic Potential
    • 26
    • Highly Influenced
    • Open Access
    Modulatory effects of cannabinoids on brain neurotransmission
    • 13


    Publications referenced by this paper.
    A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
    • 130
    • Open Access
    Cannabis and psychiatric disorders: it is not only addiction
    • 172
    Cannabidiol monotherapy for treatment-resistant schizophrenia
    • 139
    Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
    • 508
    • Highly Influential
    • Open Access
    Cannabidiol as a potential treatment for psychosis
    • 61
    • Open Access
    Cannabidiol for the treatment of psychosis in Parkinson’s disease
    • 188
    Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms
    • 394
    • Open Access